Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 07:30 ET | Source: Tris Pharma, Inc.

Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer

This Role Reflects the Company’s Commitment to Integrated Innovation Across Central Nervous System Disorders. Appointment Comes as Tris Prepares to Submit a New Drug Application (NDA) for...
April 08, 2026 07:30 ET | Source: Tris Pharma, Inc.

Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix

– Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety profile following abdominoplasty and bunionectomy – –...
March 06, 2026 15:05 ET | Source: Tris Pharma, Inc.

Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate painIn both...
February 26, 2026 07:30 ET | Source: Tris Pharma, Inc.

Tris Pharma to Present Debut Data from Phase 3 ALLEVIATE 1-2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate...
January 08, 2026 08:30 ET | Source: Tris Pharma, Inc.

Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain

– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR...